ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
Characterization of skin and soft tissue adverse reaction after saphenous vein closure using cyanoacrylate.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCyanoacrylate closure (CAC) is a minimally invasive, nonthermal treatment for varicose veins. However, regarding postoperative skin and soft tissue adverse reactions, their clinical characteristics remain poorly defined. This study compared adverse reactions after CAC and thermal ablation (TA) and characterized their features following CAC.
methodsWe retrospectively reviewed 511 patients treated for saphenous vein incompetence (300 CAC cases and 211 TA cases). Skin and soft tissue adverse reactions, defined as reactions requiring oral medication or surgical intervention, were evaluated.
resultsBaseline characteristics were similar between the groups, and no severe systemic reactions were observed. Skin and soft tissue adverse reactions occurred more frequently after CAC than after TA (34/300 [11%] vs 8/211 [4%]; P = .004). Higher CEAP classes were associated with increased reaction rates. Adverse reactions after TA were mainly related to thermal injury, including burns, phlebitis, cellulitis, and nerve-related symptoms perceived in the skin, whereas hypersensitivity-type reactions were observed only after CAC. CAC-related adverse reactions appeared to involve multiple contributing factors and were classified into five types based on particularly prominent clinical features: allergic contact dermatitis, phlebitis, exacerbated edema with induration, generalized urticaria, and foreign-body granuloma. CAC-related adverse reactions were more frequent in great saphenous vein treatment than in small saphenous vein treatment (59/520 [11.3%] vs 23/302 [7.6%]), and occurred exclusively with below-knee access. Adverse reactions were also more common in patients with hypertension. The onset of CAC-related adverse reactions occurred immediately (2.9%), at 1 week (32.3%), 2 weeks (26.5%), 3 weeks (26.5%), 4 weeks (5.9%), or >4 weeks (5.9%), whereas 75% of TA-related adverse reactions occurred within 1 week. Persistent subjective symptoms lasting ≥1 month, including pain, neuropathy, or discomfort, were less frequent after CAC than after TA (4/300 [1%] vs 14/211 [7%]; P = .0044).
conclusionsCAC was associated with more complex and delayed adverse reactions compared with TA. Awareness of these characteristic patterns is important for patient selection, counseling, risk assessment, and postoperative management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.